Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs).

被引：0
|
作者：
Vitale, Nuzzo Pier
Pond, Gregory Russell
Abou Alaiwi, Sarah
Nassar, Amin
Flippot, Ronan
Choueiri, Toni K.
Harshman, Lauren Christine
Sonpavde, Guru
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] McMaster Univ, Dept Oncol, Hamilton, ON, Canada
[3] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[4] Hop Piti Salpetriere, Lab Avec Fdn, Paris, France
[5] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA
[6] Harvard Med Sch, Boston, MA 02115 USA
[7] Stanford Univ, Sch Med, Stanford, CA 94305 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16038
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) predicts succeeding onset of immune-related adverse events (irAEs)
    Kizawa, R.
    Miura, Y.
    Oda, Y.
    Nagaoka, Y.
    Masuda, J.
    Ozaki, Y.
    Kondoh, C.
    Moriguchi, S.
    Takahashi, Y.
    Ogawa, K.
    Hashimoto, Y. Tanabe
    Taniguchi, S.
    Okaneya, T.
    Kishi, A.
    Hayashi, N.
    Takaya, H.
    Takano, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [22] Multiomic analysis of immune-related adverse events (irAEs) in melanoma patients treated with anti-PD1-based immune checkpoint inhibitors (ICIs)
    Dimitriou, F.
    Cheng, P.
    Saltari, A.
    Staeger, R.
    Tastanova, A.
    Levesque, M.
    Long, G.
    Becher, B.
    Dummer, R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S275 - S275
  • [23] Association of immune-related adverse events (irAEs) with improved clinical outcome in sarcoma patients treated with immune checkpoint blockade (ICB).
    Rosenbaum, Evan
    Seier, Kenneth
    Kelly, Ciara Marie
    Kiesler, Hannah
    Martindale, Moriah
    Nicholls, Cory
    Chi, Ping
    Dickson, Mark Andrew
    Gounder, Mrinal M.
    Keohan, Mary Louise
    Movva, Sujana
    Nacev, Benjamin
    Hwang, Sinchun
    Qin, Li-Xuan
    D'Angelo, Sandra P.
    Tap, William D.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] Management of Immune-Related Adverse Events from Immune-Checkpoint Inhibitors in Advanced or Metastatic Renal Cell Carcinoma
    Leucht, Katharina
    Ali, Nalyan
    Foller, Susan
    Grimm, Marc-Oliver
    CANCERS, 2022, 14 (18)
  • [25] Safety and efficacy outcomes in immune checkpoint inhibitor (ICI)-treated metastatic urothelial carcinoma (mUC) patients (pts) requiring treatment interruption (TI) due to immune-related adverse events (irAEs).
    Nizam, Amanda
    Sheng, Iris Yeong-Fung
    Allman, Kimberly D.
    Martin, Allison
    Gilligan, Timothy D.
    Gupta, Shilpa
    Ornstein, Moshe Chaim
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [26] Patterns of immune-related adverse events (irAEs) in adolescent and young adult (AYA) patients with melanoma receiving immune checkpoint inhibitors (ICIs)
    He, Jiasen
    John, Ida
    Afridi, Faraz
    Sun, Mianen
    Wang, Yinghong
    Roth, Michael
    McQuade, Jennifer Leigh
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Association of immune-related adverse events with immune-checkpoint inhibitors and treatment response in melanoma patients.
    Rodriguez, Benigno
    Martinez-Herrera, Jose Fabian
    Zepeda, Lorena Lopez
    Olivares, Guillermo
    Villalobos, Alberto
    Perez, Fernando
    Limas, Christian Patricio Camacho
    Serrano, Juan Alberto
    Villamayor, Omar Serrano
    Lopez, Ervin Saul Enciso
    Gerson, Daniela Shveid
    Sanchez, Efrain Isaias Camarin
    Molina, Diana Bonilla
    Cabrera, Juan Manuel Tovar
    Nehmad, Cecilia
    Whaley, Juan Jose Juarez -Vignon
    Gerson, Raquel
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Real world outcomes of immune-related adverse events (irAEs) among patients receiving immune checkpoint inhibitors (ICIs) in hospital settings
    George, S.
    Zheng, Y.
    Kim, R.
    Yu, T.
    Dreyfus, J.
    Gayle, J. A.
    Wassel, C.
    Phatak, H.
    ANNALS OF ONCOLOGY, 2019, 30 : 522 - 522
  • [29] Immune-related adverse events (irAEs) and survival in solid tumors treated with immune checkpoint inhibitors (ICIs): A systematic review and meta-analysis.
    Grizzi, Giulia
    Petrelli, Fausto
    Ghidini, Michele
    Ghidini, Antonio
    Ratti, Margherita
    Panni, Stefano
    Cabiddu, Mary
    Ghilardi, Mara
    Borgonovo, Karen
    Parati, Maria Chiara
    Barni, Sandro
    Tomasello, Gianluca
    Passalacqua, Rodolfo
    Berruti, Alfredo
    Brighenti, Matteo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Autoimmune panels as predictors of immune-related adverse events (irAEs) in patients (pts) treated with immune checkpoint inhibitors (ALERT)
    Genta, S.
    Yee, N.
    Keshavarzi, S.
    Heirali, A.
    Hansen, A. R.
    Siu, L. L.
    Saibil, S.
    Stayner, L-A.
    Yanekina, M.
    Pimentel Muniz, T.
    Vilbert, M.
    Bedard, P.
    Abdul Razak, A. R.
    Coburn, B.
    Chruscinski, A.
    Spreafico, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S844 - S845
12345